Joint Formulary & PAD

Risperidone - Schizophrenia and other psychoses

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Blue
Formulations :
  • Oral solution
  • Tablets
Associated Icons :
Restrictions / Comments :
 

Status 2

Red
Formulations :
  • Oro-dispersible tablets
Associated Icons :
R
SPC
Restrictions / Comments :
Important

Only for use where the liquid formulation is unsuitable e.g. for supervised administration to ensure compliance.

 

Status 3

Non Formulary
Formulations :
  • Depot injection
Associated Icons :
NFD1
SPC
Restrictions / Comments :
Important

Only for continuation in existing patients.

Documentation

  • No records returned.

PAD Profile

ChemicalSubstance :
Risperidone
Indication :
Schizophrenia and other psychoses
Group Name :
Keywords :
Brand Names Include :
Important Information :

For acute and chronic psychoses.

Initiation by a Mental Health specialist and stabilisation for a minimum of 1 month before any request to transfer prescribing responsibility.

Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
0
Traffic Light Entries :
3

Committee Recommendations (1)

The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed the length of prescribing of anti-psychotics by the specialist team at Surrey & Borders Partnership NHS Foundation Trust as:

Mental Health? specialist initiation and prescribing for at least 1 month and until the patient is stabilised on treatment prior to transfer of care to primary care.

Where a stabilised patient requires a simple, non-complex and non-urgent dose adjustment, this can be managed in primary care on recommendation by the specialist team.